Log in
NASDAQ:EBIO

Eleven Biotherapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume15.58 million shs
Average Volume2.86 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
Read More
Eleven Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EBIO
CUSIPN/A
Phone(617) 444-8550
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive EBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for EBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) released its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.03.
View Eleven Biotherapeutics' earnings history
.

Who are some of Eleven Biotherapeutics' key competitors?

What other stocks do shareholders of Eleven Biotherapeutics own?

Who are Eleven Biotherapeutics' key executives?

Eleven Biotherapeutics' management team includes the following people:
  • Thomas R. Cannell, President, Chief Executive Officer & Director
  • Monica Forbes, Chief Financial Officer & Vice President
  • Jeannick Cizeau, Head of Research
  • Glen C. MacDonald, Chief Technology Officer
  • David Brooks, Senior Vice President-Clinical Development

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

What is Eleven Biotherapeutics' official website?

The official website for Eleven Biotherapeutics is www.elevenbio.com.

How can I contact Eleven Biotherapeutics?

Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 444-8550 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.